PD173074

Name: PD173074
Brand: Selleck Chemicals
SKU: S1264
Rating: 5 (97 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1264

97 publications

CAS No. 219580-11-7

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src. PD173074 reduces proliferation and promotes apoptosis in gastric cancer cells.

Selleck's PD173074 has been cited by 97 publications

Cell Stem Cell, 2020, S1934-5909(20)30541-5

PubMed: 33271070 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):504-518

PubMed: 30827889 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Genet, 2015, 47(9):1003-10

PubMed: 26258846 ( click the link to review the publication )

Nat Methods, 2014, 11(8):855-60

PubMed: 24930130 ( click the link to review the publication )

Cancer Discov, 2013, 3(6):636-47

PubMed: 23558953 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Adv Sci (Weinh), 2021, 8(2):2002922

PubMed: 33511016 ( click the link to review the publication )

Nat Commun, 2021, 12(1):3017

PubMed: 34021145 ( click the link to review the publication )

EMBO J, 2021, e107182

PubMed: 34086370 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(9)4720

PubMed: 33946884 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-021-01061-1

PubMed: 33829354 ( click the link to review the publication )

NPJ Precis Oncol, 2021, 5(1):65

PubMed: 34267282 ( click the link to review the publication )

J Exp Med, 2020, 3;217(8):e20191805

PubMed: 32434218 ( click the link to review the publication )

Leukemia, 2020, 14

PubMed: 32409689 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2020, 202008017

PubMed: 32989154 ( click the link to review the publication )

Redox Biol, 2020, 38:101780

PubMed: 33171331 ( click the link to review the publication )

Front Oncol, 2020, 10;10:331

PubMed: 32211337 ( click the link to review the publication )

Front Oncol, 2020, 10:584505

PubMed: 33425737 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(9)E3214

PubMed: 32370101 ( click the link to review the publication )

Front Pharmacol, 2020, 11:154

PubMed: 32184729 ( click the link to review the publication )

Neuroscience, 2020, 1;436:1-10

PubMed: 32278061 ( click the link to review the publication )

PLoS One, 2020, 15(6):e0234708

PubMed: 32555680 ( click the link to review the publication )
Int J Mol Sci, 2020, 21(3)

PubMed: 32024006 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Stem Cell Res, 2020, 48:101951

PubMed: 32798915 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-0713

PubMed: 31409615 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-18-2779

PubMed: 31515463 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2331-2344

PubMed: 31461650 ( click the link to review the publication )

Elife, 2019, 8

PubMed: 30720426 ( click the link to review the publication )

Development, 2019, 146(14)

PubMed: 31320324 ( click the link to review the publication )

Cells, 2019, 8(3)

PubMed: 30866584 ( click the link to review the publication )

Exp Neurol, 2019, 317:34-50

PubMed: 30802446 ( click the link to review the publication )

Lab Invest, 2019, 10.1038/s41374-019-0256-3

PubMed: 31028279 ( click the link to review the publication )

Sci Rep, 2019, 9(1):7037

PubMed: 31065021 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

ACS Comb Sci, 2019, 21(12):805-816

PubMed: 31689077 ( click the link to review the publication )

Oncotarget, 2019, 10(11):1171-1192

PubMed: 30838090 ( click the link to review the publication )

Stem Cell Reports, 2018, 10(4):1308-1323

PubMed: 29526737 ( click the link to review the publication )

Cell Physiol Biochem, 2018, 47(1):151-160

PubMed: 29763898 ( click the link to review the publication )

Osteoarthritis Cartilage, 2018, 26(12):1733-1743

PubMed: 30201491 ( click the link to review the publication )

Mol Oncol, 2018, 10.1002/1878-0261.12422

PubMed: 30537101 ( click the link to review the publication )

Cells, 2018, 7(12)

PubMed: 30544798 ( click the link to review the publication )

J Cell Sci, 2018, 131(18)

PubMed: 30154213 ( click the link to review the publication )

Int J Biol Sci, 2018, 14(10):1389-1398

PubMed: 30123084 ( click the link to review the publication )

Front Neurosci, 2018, 12:582

PubMed: 30210273 ( click the link to review the publication )
Cancer Biol Ther, 2018, 19(1):76-86

PubMed: 29257923 ( click the link to review the publication )

Dev Biol, 2018, 433(2):394-403

PubMed: 29291983 ( click the link to review the publication )

Dev Biol, 2018, 433(2):416-432

PubMed: 28760345 ( click the link to review the publication )

Biomed Pharmacother, 2018, 103:1516-1525

PubMed: 29864937 ( click the link to review the publication )

Nat Commun, 2017, 8;8:15617

PubMed: 28593995 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):962-973

PubMed: 27535980 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2017, 9(45):39185-39196

PubMed: 29045789 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Sci Rep, 2017, 7:41986

PubMed: 28155881 ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2017, ajpendo.00328.2016

PubMed: 28174179 ( click the link to review the publication )

PLoS One, 2017, 12(2):e0171898

PubMed: 28207787 ( click the link to review the publication )

J Orthop Sci, 2017, 22(6):1112-1119

PubMed: 28877850 ( click the link to review the publication )

Oncotarget, 2017, 8(54):91841-91859

PubMed: 29190880 ( click the link to review the publication )

Tumour Biol, 2017, 39(7):1010428317712592

PubMed: 28718374 ( click the link to review the publication )

Stem Cell Reports, 2017, 8(1):84-94

PubMed: 28076758 ( click the link to review the publication )

Nat Commun, 2016, 7:13796

PubMed: 27982029 ( click the link to review the publication )

Cancer Res, 2016, 10.1158/0008-5472.CAN-16-0058

PubMed: 27231203 ( click the link to review the publication )

Cancer Res, 2016, 76(22):6471-6482

PubMed: 27671675 ( click the link to review the publication )

Biomaterials, 2016, 78:115-28

PubMed: 26691234 ( click the link to review the publication )

J Neurosci, 2016, 36(16):4534-48

PubMed: 27098696 ( click the link to review the publication )

Cell Oncol (Dordr), 2016, 39(3):229-42

PubMed: 26883759 ( click the link to review the publication )

Dev Biol, 2016, 415(2):228-241

PubMed: 26988119 ( click the link to review the publication )

Development, 2016, 143(23):4368-4380

PubMed: 27660325 ( click the link to review the publication )
Oncotarget, 2016,

PubMed: 27153554 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(12):1736-44

PubMed: 26473643 ( click the link to review the publication )

Cancer Res, 2015, 75(5):880-91

PubMed: 25432174 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(12):2831-9

PubMed: 26438159 ( click the link to review the publication )

Carcinogenesis, 2015, 36(1):32-40

PubMed: 25344834 ( click the link to review the publication )

Cancer Sci, 2015, 106(10):1278-87

PubMed: 26183471 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )

Growth Factors, 2015, 33(5-6):356-65

PubMed: 26607681 ( click the link to review the publication )

Gut, 2014, 63(12):1932-42

PubMed: 24658599 ( click the link to review the publication )

Blood, 2014, 123(10):1516-24

PubMed: 24408322 ( click the link to review the publication )

Hepatology, 2014, 59(4):1427-34

PubMed: 24122810 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Neoplasia, 2014, 16(8):644-55

PubMed: 25220592 ( click the link to review the publication )

J Cell Sci, 2014, 127(Pt 23):5079-92

PubMed: 25278553 ( click the link to review the publication )

J Cell Sci, 2014, 127(23):5079-92

PubMed: ( click the link to review the publication )

Breast Cancer Res Tr, 2014, 143(3):435-46

PubMed: 24398778 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(12):1613-21

PubMed: 25535896 ( click the link to review the publication )

PLoS One, 2014, 9(4):e95434

PubMed: 24752320 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(12):1585-96

PubMed: 24092775 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

Celon Pharma Inc, 2013, Paulina Grygielewicz

PubMed: ( click the link to review the publication )

PLoS Genet, 2012, 8(2):e1002500

PubMed: 22383889 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(9):745-57

PubMed: 22700489 ( click the link to review the publication )
Clin Exp Metastasis, 2012, 30(4):507-20

PubMed: 23212305 ( click the link to review the publication )

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description

Targets

FGFR1 ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)
~25 nM	100 nM-200 nM

In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with K_i of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. ^[1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. ^[2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. ^[3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
NCI-H1581	M4e5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmLhTWM2OD1yLkCxNlI2KM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
KG-1	M3vsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVLJR\|UxRTBwMEWxNlkh\|ryP	M1\teFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MFM-223	M2rpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUXJR\|UxRTBwMkG1O\|Yh\|ryP	NV7MTmZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
EoL-1-cell	NGi0[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2fTcGlEPTB;MD6zNlk5PCEQvF2=	NHvxWFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
ECC10	NHLsUoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NF2zfllKSzVyPUCuN\|M5QThizszN	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
H-EMC-SS	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWXxPVE2UUN3ME2wMlM1PzF3IN88US=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
AN3-CA	MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NEDCc2dKSzVyPUCuOFAyOzNizszN	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
HuO-3N1	MknXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M3T4dmlEPTB;MD61OFY2OyEQvF2=	NGDFXpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
RT-112	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2jWNmlEPTB;MD61OFcxOSEQvF2=	Mk\oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NEC8	MkTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlrkTWM2OD1yLkW2Nlg6KM7:TR?=	NHHiW4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
D-263MG	NHjueY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnzzTWM2OD1yLkexNVU6KM7:TR?=	M{nXc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SW962	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnT3TWM2OD1yLke4PVg5KM7:TR?=	M2TBfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
BV-173	MlfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUTJR\|UxRTBwOES2NlMh\|ryP	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MFE-280	M2PNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NX[xNoU4UUN3ME2wMlg2QDd{IN88US=>	NYnheJlwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HuH-7	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlfrTWM2OD1zLkK0OFY1KM7:TR?=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
RS4-11	NILjXlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M2j0O2lEPTB;MT6zN\|g5PiEQvF2=	NInySpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
DMS-114	NUnTeXFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{L1S2lEPTB;MT6zOlc{PyEQvF2=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MSTO-211H	NYr1RmZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NUXEdYZOUUN3ME2xMlQ4Ozd6IN88US=>	MlzJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
DU-145	M{TXZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NXfscYNmUUN3ME2xMlU5OjF5IN88US=>	NIXlOpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
A172	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4fyeGlEPTB;MT63NFM2PSEQvF2=	MmDBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SBC-1	M2fwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlS0TWM2OD1{LkC5OEDPxE1?	MnHiQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
H9	NHfybI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVnJR\|UxRTJwMUSzNFYh\|ryP	NFjDUYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-SNU-1	NXfFNnZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MV;JR\|UxRTJwMUizPVQh\|ryP	NWLO[2VjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H720	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MXfJR\|UxRTJwMkGyPFMh\|ryP	NIPFXVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HCC2218	MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWjJR\|UxRTJwM{e5N\|kh\|ryP	NGPRO2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
G-401	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			Ml[2TWM2OD1{LkS3NVg6KM7:TR?=	MoLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MPP-89	NUL2Om1pT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGnCb3pKSzVyPUKuOFg{PjRizszN	NFu2VIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
697	M{GxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NE\rSnpKSzVyPUKuOlU{OzFizszN	M3LFT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
KARPAS-45	MoLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1zpXmlEPTB;Mj63NFc1PyEQvF2=	M{H4eFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MG-63	NUGwUoFjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGTzZlNKSzVyPUKuPVQzPjJizszN	NGTYPIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NTERA-S-cl-D1	M33DSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFj2WYNKSzVyPUOuNFM1PzJizszN	NID5RXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
G-402	NV;xNXZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M37NbGlEPTB;Mz6xNlczPyEQvF2=	NHXwcZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NKM-1	NUPkdFRmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3fwdWlEPTB;Mz6xN\|U3PCEQvF2=	MoTrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
RH-18	MonjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnvxTWM2OD1\|LkG5OVk5KM7:TR?=	NET0Olk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H1092	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXzNdFR1UUN3ME2zMlE6PjlizszN	NYP5W5lJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
RPMI-8226	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEi2OVFKSzVyPUOuNlM1PDdizszN	NG\GUHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
GAMG	MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYfJR\|UxRTNwNE[1O\|Yh\|ryP	NYfFWXVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HH	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M17GdWlEPTB;Mz60O\|Y4PiEQvF2=	MoW0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
RO82-W-1	NXe5bIFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3\xUWlEPTB;Mz60PVg2PSEQvF2=	NWLpSmV4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
CCRF-CEM	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NEjKfW9KSzVyPUOuOVA1QDhizszN	NEnoXIo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NBsusSR	M1nNT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NHO5WIFKSzVyPUOuOlM6PjlizszN	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
CHL-1	MmS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1[2bGlEPTB;Mz62OVc6QSEQvF2=	NGrlZY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
LK-2	M2jWbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mor5TWM2OD1\|Lk[3NVM{KM7:TR?=	M4\rdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
Hs-578-T	MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlvHTWM2OD1\|Lk[3PFc{KM7:TR?=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
CTB-1	NYnhUW85T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MojJTWM2OD1\|LkiwNFUyKM7:TR?=	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
ES5	NEf3NIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4OzbGlEPTB;Mz64N\|Y{PyEQvF2=	MoTjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
A204	M3rkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NG\6coNKSzVyPUOuPVIxPzVizszN	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SW780	NVXjWZQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHXreldKSzVyPUOuPVIzPDVizszN	NV3YS5RORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
EW-3	NHLnOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3;Tb2lEPTB;Mz65PFkzOyEQvF2=	NFTYSFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
A704	NYDXd2hqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MorXTWM2OD12LkK4O\|I{KM7:TR?=	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
LU-139	NInxRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHHEcJJKSzVyPUSuN\|E2OzRizszN	NHHTVFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
CAL-72	NV3udo1NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoHSTWM2OD12LkSxO\|Q3KM7:TR?=	MonnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
D-336MG	NHnY[2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NGnIUWNKSzVyPUSuOFY5OTdizszN	NFfMXXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
LAMA-84	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUTJR\|UxRTRwNUOzNUDPxE1?	NVi5NVNxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
GI-ME-N	M1fIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NYLEOlRbUUN3ME20MlU1QDFizszN	NUj1PZozRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
KM-H2	MnPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4nCe2lEPTB;ND61OVIzOiEQvF2=	NHnxbXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H209	NWf5U2plT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M2\PS2lEPTB;ND61PFI5OyEQvF2=	MniyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
IGROV-1	NFnwT\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnzzTWM2OD12Lki3NVY5KM7:TR?=	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
L-363	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3LndmlEPTB;ND65OlY3PSEQvF2=	MnHhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-3	NV\VTFdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVPrNYQxUUN3ME21MlI1ODZizszN	MnW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HuO9	MoDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M17JSWlEPTB;NT6zPFg1OyEQvF2=	M33id\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
NOS-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2DofGlEPTB;NT63NlkzPyEQvF2=	MmO1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H1770	NIXDOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXLJR\|UxRTVwOUWwN\|Ih\|ryP	M{nQdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SF126	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmTuTWM2OD14LkKxOFA3KM7:TR?=	M2DqXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
ML-2	NGTPU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnjuTWM2OD14LkK0PVc4KM7:TR?=	MonZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
CHP-134	MmL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NV\ndpdiUUN3ME22MlI2OTh{IN88US=>	NFTzS4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H1355	NX\oUYZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4LzU2lEPTB;Nj60NVc{OyEQvF2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
TE-12	Mlz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NHPZPZRKSzVyPU[uO\|I3PzFizszN	NH3Zb4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
A4-Fuk	MlP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWPJR\|UxRTZwN{OxOFIh\|ryP	NYX3Vo9ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MV-4-11	M2DaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3X5bWlEPTB;Nj63OlYzPiEQvF2=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SK-UT-1	M3O5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUXwPGU1UUN3ME22MlkyPzh2IN88US=>	NXLqR5lLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
J-RT3-T3-5	NXv1b\|FDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NEi3XVdKSzVyPUeuNFc4PjRizszN	NXG3ZXFNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
ME-180	M{C2dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MlfUTWM2OD15LkGwOFA1KM7:TR?=	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SK-MEL-28	NI\BZm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIizSJVKSzVyPUeuN\|c5OTlizszN	NWDQV2ZkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HAL-01	M4jlTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1;FSGlEPTB;Nz60PFM1OSEQvF2=	NHnPNoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
ES8	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2noWWlEPTB;Nz62PVYzPiEQvF2=	MoXWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
DB	M4ru[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUfJR\|UxRThwMUG1NFQh\|ryP	MlL1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SK-NEP-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXna[JFGUUN3ME24MlQ5OTR7IN88US=>	NYTm[WJqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
COR-L88	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NX7tNldtUUN3ME24MlUxQThzIN88US=>	NVLxbY5oRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
LB1047-RCC	MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWTJR\|UxRThwNUKyNVIh\|ryP	MkLPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H520	NUDNNXBZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGjyeWFKSzVyPUiuOlIyPTdizszN	M4HhTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SW954	NYLhTVZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1;QdmlEPTB;OD62PVc5PiEQvF2=	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
TE-6	NYXMWJE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHvLcoRKSzVyPUiuO\|UyPDNizszN	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
D-283MED	M{CzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NWTlXFR2UUN3ME25MlA3PTN2IN88US=>	MnPJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
DBTRG-05MG	NVrpZoE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NXf1[VdWUUN3ME25MlA6PjB5IN88US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H446	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NF;Xc5ZKSzVyPUmuNlk2OjZizszN	MnnwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HOS	NX;BR21zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MVXJR\|UxRTlwM{WxN\|Qh\|ryP	NUD5Vpc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
ES4	M{TVdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NW\GbYp{UUN3ME25MlUxPTl3IN88US=>	NHvZRo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
EW-13	NFPudGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVjtO4NyUUN3ME25Mlg6ODV3IN88US=>	M1jT[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
IST-MES1	M{jqWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MWHJR\|UxRTlwOUS1N\|Qh\|ryP	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
CAS-1	MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlrnTWM2OD17Lkm3OlU6KM7:TR?=	NYT4VIpbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
EM-2	Mn7FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWLJR\|UxRTFyLkGzPVMh\|ryP	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SW948	MoXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MXnJR\|UxRTFyLkG4PFIh\|ryP	NI\JeJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
OAW-42	NWXpUlY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlywTWM2OD1zMD61NlY4KM7:TR?=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
BE-13	M1rVWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mmj0TWM2OD1zMD62OVc3KM7:TR?=	Mn:3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
KU812	MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVTJR\|UxRTFyLkezPVEh\|ryP	M3zrd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SK-MEL-30	MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M1[yNWlEPTB;MUCuPFkxOSEQvF2=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
A2780	M3;IRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2K3fGlEPTB;MUGuNFMxQCEQvF2=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
TGBC24TKB	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2jwfWlEPTB;MUGuNFc{PyEQvF2=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
GOTO	NU\BVVZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlTCTWM2OD1zMT6yNFg1KM7:TR?=	MoXRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H526	MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFSzSWVKSzVyPUGxMlM5OzdizszN	NITjUXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
BHT-101	MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWjJR\|UxRTFzLkS0OVYh\|ryP	NH3Obos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H1155	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYfJR\|UxRTFzLkS5OFch\|ryP	NFHNVHU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MCF7	Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIfafGNKSzVyPUGxMlYyPjdizszN	MkHVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MKN45	M1v1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2XqOmlEPTB;MUGuO\|k6OyEQvF2=	MlrXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MOLT-16	NH;yTJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NULmflREUUN3ME2xNU46Pjl{IN88US=>	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
YH-13	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NGXBZ3ZKSzVyPUGyMlA{PDZizszN	M2rXTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
P12-ICHIKAWA	NI\NTGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXvJR\|UxRTF{LkO4OFUh\|ryP	NXHvW3pIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
GR-ST	NHzLVJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NXHkeZZRUUN3ME2xNk42Ojl3IN88US=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
CAKI-1	NH7SPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NHzHWmlKSzVyPUGyMlc6OSEQvF2=	M3\3R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LXF-289	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2fFRmlEPTB;MUOuNFg{PSEQvF2=	NUn4WJp{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MHH-PREB-1	M{nyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NEPvU3BKSzVyPUGzMlI4ODRizszN	NXzCOItoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
EW-16	NXHC[ZlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NYLTPVh7UUN3ME2xN{4{OTh5IN88US=>	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H82	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYDle\|R7UUN3ME2xN{41OTl3IN88US=>	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MMAC-SF	M2XT[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoDqTWM2OD1zMz60OVQ4KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
COLO-684	NFnGNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NVrRO4s6UUN3ME2xN{42OzF6IN88US=>	MoezQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
QIMR-WIL	M4\ZVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkfJTWM2OD1zMz64NVA6KM7:TR?=	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NB69	MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MYfJR\|UxRTF\|Lkm4Olgh\|ryP	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H2291	NH\oc25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NEnCfJBKSzVyPUG0MlQ1PTNizszN	NHHyPXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
MKN7	MkfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Ml;RTWM2OD1zND62Olc3KM7:TR?=	NWrwNYRLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HDLM-2	M33TfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			Mon5TWM2OD1zNT6xNlg3KM7:TR?=	MmjRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
A253	NIqwc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVfJR\|UxRTF3LkO4Olkh\|ryP	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SK-LU-1	M4nYSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXrJR\|UxRTF3LkmwPVQh\|ryP	M2S1fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MEG-01	M{jzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmTjTWM2OD1zNT65NVA4KM7:TR?=	NUDRT4lDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SK-N-DZ	NWPEOWpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUPJR\|UxRTF3LkmzO\|Yh\|ryP	NYXuNnpmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
H4	NHPSZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MlmxTWM2OD1zNj6wPFgh\|ryP	M1HON\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LU-65	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmK0TWM2OD1zNj6zN\|g1KM7:TR?=	NHrocWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H1048	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIC3[ZJKSzVyPUG2MlUyPjVizszN	NEDzRXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
LCLC-97TM1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1rWcGlEPTB;MU[uOVg5QSEQvF2=	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
CAL-120	MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnLqTWM2OD1zNj65PFc6KM7:TR?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
LU-134-A	NUSwOFhZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NWLsS2N[UUN3ME2xO{4{OzlzIN88US=>	Mn7qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SK-MEL-1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MofCTWM2OD1zNz63NVI4KM7:TR?=	NHXW[Jo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H69	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MlrGTWM2OD1zNz65N\|A4KM7:TR?=	M{PVZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MC116	M17jTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MV\JR\|UxRTF5Lkm3OUDPxE1?	MmTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
UMC-11	NWXXSlVKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M1fFV2lEPTB;MUiuNVc5QCEQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
HCC1395	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmjWTWM2OD1zOD60N\|AyKM7:TR?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
no-10	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MmfPTWM2OD1zOD62N\|g5KM7:TR?=	MoO0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NY	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			Mlm2TWM2OD1zOT6wPFA6KM7:TR?=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
OS-RC-2	NUjvOFVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3:3bWlEPTB;MUmuNVI2OiEQvF2=	M{S2TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
D-423MG	NWLRXndKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NIT1bZJKSzVyPUG5MlM6PTJizszN	M2HWeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LC-2-ad	NHyxRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MkHsTWM2OD1zOT63OlEzKM7:TR?=	M3PDeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
DU-4475	NWjSbXQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVzzdGxKUUN3ME2xPU45QDV{IN88US=>	MnSxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
YKG-1	M2n4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M1G1OWlEPTB;MUmuPVYzKM7:TR?=	NGf1SJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HCC1569	MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NYrYcldCUUN3ME2yNE4zPjJ2IN88US=>	NGG4S3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
TYK-nu	NIfQOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NIHXRnpKSzVyPUKwMlI5PDdizszN	NX\Xc\|JMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
DEL	MnH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{n1ZWlEPTB;MkCuPVgxQCEQvF2=	NWPSeJo4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MHH-ES-1	M1LncGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MXjJR\|UxRTJzLkO1PVch\|ryP	NH;mXZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
KARPAS-299	MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NIj4OVNKSzVyPUKxMlUzQSEQvF2=	M1;YN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
CTV-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXf3OVd6UUN3ME2yNU43OTd{IN88US=>	MmjNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H2452	NIX2R4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NFvqfVZKSzVyPUKyMlY3PzdizszN	NILrSms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
D-566MG	NYexRYlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Mn;pTWM2OD1{Mj63OlAyKM7:TR?=	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
EFO-27	NHfyZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MXLJR\|UxRTJ\|LkC2OVEh\|ryP	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H596	NXPQ[mZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHT1TolKSzVyPUKzMlg2OjdizszN	NEO5OIE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
KS-1	M3zTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M{\1SGlEPTB;MkSuNlc2QSEQvF2=	MlHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
8305C	NEDzfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYDJR\|UxRTJ2LkSwOFUh\|ryP	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
A427	NYTUfY0xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHjZZoFKSzVyPUK1MlA{OjNizszN	M1rqeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
COLO-800	NYX5OncyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVT1VoVFUUN3ME2yOU4yODZzIN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SJRH30	M37JNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkDZTWM2OD1{NT6zPVA5KM7:TR?=	NXXlbIluRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MEL-HO	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NIftTldKSzVyPUK1MlQ{OTlizszN	NWr6eFR{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
FTC-133	NXrzb\|VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MlrCTWM2OD1{NT64NVg3KM7:TR?=	Ml23QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SF295	NHXhTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M4HXWmlEPTB;Mk[uNlk3KM7:TR?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SW1710	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M2Xob2lEPTB;Mk[uOFEzOyEQvF2=	NUXnTFZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
EFM-19	NIqyVnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUfud2FrUUN3ME2yOk45OTR3IN88US=>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NB10	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NXfJeYJQUUN3ME2yPE4zOjl5IN88US=>	M17kRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
TK10	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NYm2XJNkUUN3ME2yPE4zOzl7IN88US=>	Mnm4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
D-502MG	Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MWDJR\|UxRTJ6LkSg{txO	M2TGWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
EW-18	M{nOfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3THT2lEPTB;MkiuOFM5PiEQvF2=	MoLjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
VMRC-RCZ	MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlGzTWM2OD1{OD65OFEh\|ryP	NX;aSG9VRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
Ca9-22	NWjDSlJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			Ml;rTWM2OD1{OT60OVU4KM7:TR?=	NILCZZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
KYSE-70	M3Tm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4TyOGlEPTB;MkmuOVc5PiEQvF2=	MnT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
A101D	M{Xzc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFvyV\|BKSzVyPUK5MlY1PzJizszN	M33qc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
WM-115	NHfNeJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUTJR\|UxRTJ7Lke2NFch\|ryP	M{TCWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
HCC2157	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NVjMWWdZUUN3ME2yPU45QDB5IN88US=>	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
TE-9	M1H6TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFOwcFhKSzVyPUK5Mlg5PjVizszN	M4jtSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
K-562	NFzBW2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnHHTWM2OD1\|MD6wPVM{KM7:TR?=	M3LNfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SN12C	NYTwb2dFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M3ey[mlEPTB;M{CuNVQzPiEQvF2=	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
ESS-1	NXLFTG4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmDZTWM2OD1\|MD60O\|U6KM7:TR?=	Ml2zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
K5	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NH;IeVdKSzVyPUOwMlc3PCEQvF2=	M{TRUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
J82	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NUPJ[HhNUUN3ME2zNU4xQDl5IN88US=>	NEXGOXc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HOP-92	NF7OcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			M3;3VGlEPTB;M{GuNVEyOSEQvF2=	NICwS\|Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H2228	NID1UXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NUHuXYtRUUN3ME2zNU4{Ojl4IN88US=>	M{X6WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
OCI-AML2	NXy1dFJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NGjtWG1KSzVyPUOxMlM3OSEQvF2=	NEXDOGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-SNU-5	M2HvOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MVPJR\|UxRTNzLkixN\|ch\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
A3-KAW	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4f5cmlEPTB;M{GuPVI1OyEQvF2=	NHzu[GM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
LCLC-103H	NUfySXdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NV\YdIJyUUN3ME2zNk4xOTdzIN88US=>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
KY821	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3TNNGlEPTB;M{KuOlg5PCEQvF2=	NFXY[5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
JVM-2	Mor1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlH2TWM2OD1\|Mj65NFc6KM7:TR?=	NGTJbYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
Mo-T	NXXEb2tpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHfFUYtKSzVyPUOzMlExODVizszN	M1jzXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
IA-LM	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MnW1TWM2OD1\|Mz6yO\|Uh\|ryP	M4\lelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
C8166	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{DVbWlEPTB;M{OuN\|E6OiEQvF2=	MkD3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
TCCSUP	M1zUSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MnrXTWM2OD1\|Mz60N\|A4KM7:TR?=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
JEG-3	NFHYfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MnfhTWM2OD1\|Mz60O\|Y5KM7:TR?=	MknSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MS-1	MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M2q0c2lEPTB;M{OuOVU2OSEQvF2=	NFXX[5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H1304	MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M{LrN2lEPTB;M{OuOVczPSEQvF2=	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
Ramos-2G6-4C10	Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NG[x[YZKSzVyPUO0MlA{OzVizszN	MlrrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
MDA-MB-453	NVLnTGlsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MUTJR\|UxRTN2Lk[zPVUh\|ryP	NXLjNWN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
KYSE-520	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUXJR\|UxRTN2LkexPFEh\|ryP	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
SW900	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M4SxSWlEPTB;M{SuPFEyPSEQvF2=	NFvtfGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HCC2998	M2rR[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmnYTWM2OD1\|NT6xOVI6KM7:TR?=	NXTCV4I6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
A2058	M3XqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MmPTTWM2OD1\|NT62NFYyKM7:TR?=	NVS2dIVTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
OVCAR-3	NWjodogxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmTvTWM2OD1\|Nj6yNFQ2KM7:TR?=	M{LqclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
MOLT-4	MmPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NFPvWY9KSzVyPUO2MlIzQTRizszN	M4LvW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
CAPAN-1	NVi2b3NvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MmK4TWM2OD1\|Nj60Olk6KM7:TR?=	Mlr6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SCC-9	M370Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M2DtSmlEPTB;M{euOFAzPyEQvF2=	NWrWPYI1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
SF268	NX7kcZZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NHLMWmdKSzVyPUO4MlM1OzNizszN	MlrjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
HGC-27	MnTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MUjJR\|UxRTN6LkO3NVEh\|ryP	MlrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
DOHH-2	MnH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MVzJR\|UxRTN6LkexOVgh\|ryP	NYP5R5NzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
KE-37	NH;6VFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MUDJR\|UxRTN6Lkm4Nlgh\|ryP	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
MOLT-13	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M3nlR2lEPTB;M{muNlUxOiEQvF2=	NH:1eYY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
ES1	MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M4HGemlEPTB;M{muN\|g2KM7:TR?=	MojGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
SK-OV-3	MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVrNbIJYUUN3ME2zPU46PjR\|IN88US=>	M2\kPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SNU-449	NX7MemZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M{HlNmlEPTB;NECuNFc3PCEQvF2=	NVuw[Ig{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
KYSE-510	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFvIVWtKSzVyPUSwMlEzQTVizszN	NHfz[4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
HL-60	NF3EN4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NYTPUnI{UUN3ME20NE46Pzh\|IN88US=>	NWe1TWp5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
DJM-1	MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVnGeolbUUN3ME20NE46Pzl7IN88US=>	NH7BXlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
TGBC11TKB	M1jNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NW\xUoIzUUN3ME20NU4xQTJ4IN88US=>	NXXjXmJ3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
U-2-OS	MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MoXmTWM2OD12Mj6yOlQyKM7:TR?=	MoDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H2030	M1WyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M3f6[WlEPTB;NEKuOFM3QCEQvF2=	NHnTN4Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
LU-135	M{LXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MoXSTWM2OD12Mj61OFQ4KM7:TR?=	MmK5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
ZR-75-30	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NWD0fHlbUUN3ME20N{4xPDl\|IN88US=>	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
GT3TKB	MnHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M33FemlEPTB;NEOuNlY4QSEQvF2=	NYHNXG9{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
RPMI-2650	NE\wTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MVLJR\|UxRTR\|Lke4NVYh\|ryP	M4LTflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SAS	MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MlK1TWM2OD12Mz65OVM1KM7:TR?=	NUK1TZJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
MDA-MB-231	MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkH2TWM2OD12Mz65OlA6KM7:TR?=	M3PrZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
JVM-3	MlLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MkC4TWM2OD12ND6wOVM{KM7:TR?=	M1zLOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
COLO-320-HSR	NX;4NIM6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MoDZTWM2OD12ND61OlM{KM7:TR?=	M3zPO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
SNB75	M37UeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIDLcXpKSzVyPUS0MlYyODVizszN	MkDoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H441	M2HROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MUHJR\|UxRTR2LkmzNlgh\|ryP	NVq5eYZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HCT-116	NEHVU2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NV72V2pYUUN3ME20OE46QDZ6IN88US=>	NGjtVHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-H226	NFyxWlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MW\JR\|UxRTR3Lk[zOlgh\|ryP	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
CAL-33	M2S4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			M4fJSWlEPTB;NEWuPVIyPyEQvF2=	Ml3XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
NCI-H1437	NELKdWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			MYjJR\|UxRTR4LkOyNUDPxE1?	NWe1OFVNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
HCC1187	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MUPJR\|UxRTR4LkSyOVUh\|ryP	NXn5PWk4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NUGC-3	M4HkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NFzwTJpKSzVyPUS2MlU4ODlizszN	MnfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
T98G	MkDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NVW4S5FZUUN3ME20O{42PDdizszN	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
OVCAR-8	MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			M360W2lEPTB;NEeuOlg{KM7:TR?=	M1HUelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
LB2241-RCC	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M{S2V2lEPTB;NEeuO\|I4KM7:TR?=	NVXtPFJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNOTh7NUi0M{c,W0GQR1XSQE9iRg>?
NCI-H358	NYTIO5g4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MY\JR\|UxRTR6LkGxOVIh\|ryP	MoTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMNVg6PTh2Lze+V2FPT0WUPD;hQi=>
PANC-08-13	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			M1HCeWlEPTB;NEiuNVg2OyEQvF2=	M{nqZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFE5QTV6ND:nQnNCVkeHUkyvZV4>
KP-N-YN	NEjRemhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			NWHSPYtrUUN3ME20PE4zOTB{IN88US=>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQlyxPFk2QDRxJ{7TRW5ITVJ:L3G+
NCI-H1755	M4HGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MYfJR\|UxRTR6LkK3NlYh\|ryP	NIrxfIc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
NCI-N87	Mmi4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MV7JR\|UxRTR6LkK5PVEh\|ryP	NFzZVWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmwyQDl3OESvK\|5USU6JRWK8M4E,
SUM52	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1rocVUh\GG7cx?=	NH7UbXFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF\HSnIzNWGvcHzp[olm\CCVVV21NkBk\WyuczDh[pRmeiB3IHThfZMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wNVI{KM7:TT6=	M3XvVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUKxNVU3Lz5{OEWyNVE2PjxxYU6=
RT112	M2\VTmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M2nxc\|czKGi{cx?=	MmriRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCUVEGxNkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDHTVUxKD1iMD6wNVUh\|ryPLh?=	NHTXVpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{W5PVc1Oid-Mke1PVk4PDJ:L3G+
insect cells	MU\GeY5kfGmxbjDhd5NigQ>?		NWjTeodIOTBibXnudy=>	NVLlclNjUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBnfWyuIHzlcod1cCCqdX3hckBHT0[UMTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiaX7z[YN1KGOnbHzzJIlvKHC{ZYPlcoNmKG:oIGvnZY1u[S1\|MmDdRXRRKGGodHXyJFExKG2rboOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDiZZNm\CC{YXTpc4FkfGm4ZTDmbYx1\XJiYnnu[Ilv\yCjc4PhfUwhUUN3MDC9JFAvODJzNTFOwG0v	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzlzNEO2Nkc,Ojd7MUSzOlI9N2F-
SW780	MoLmRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NY\EcFVDPSCmYYnz	M4rpb2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRlfGVlMu[W2ybHnmbYVlKFOZN{iwJINmdGy\|IHHmeIVzKDViZHH5d{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkC4OFMh\|ryPLh?=	MljJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh3MkGxOVYoRjJ6NUKxNVU3RC:jPh?=
NIH/ 3T3	MkL2SpVv[3Srb36gZZN{[Xl?		M4r4WlUhdWmwcx?=	M1Lvd2lvcGmkaYTpc44hd2ZiVlXHSnIzKCi3bnvuc5dvKG:{aXfpckkhd3[ncnX4dJJme3OnZDDpckBud3W\|ZTDOTWgwKDOWMzDj[YxteyCrbnP1ZoF1\WRiZn;yJFUhdWmwczDmc4xtd3enZDDifUB{fGmvdXzheIlwdiC5aYToJHZGT0ZiZn;yJFUhdWmwczDifUBqdW23bn;icI91fGmwZzDhcoFtgXOrczygTWM2OCB;IECuNUDPxE1w	MoD3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|Mk[zN\|koRjJ5M{K2N\|M6RC:jPh?=
NCI-H520	MWTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1rmWlch\GG7cx?=	M{HKSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRlfGVlEu[W2ybHnmbYVlKE6FST3IOVIxKGOnbHzzJIFnfGW{IEeg[IF6eyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlI5OSEQvF2u	M37UdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUKxNVU3Lz5{OEWyNVE2PjxxYU6=
HUVEC	NWjUfHRiTnWwY4Tpc44h[XO\|YYm=	Mn7XNVAhdk1?	MnjMNVQhcHK\|	MV;Jcohq[mm2aX;uJI9nKE[JRmKtcYVlcWG2ZXSgZY5ocW:pZX7ld4l{KGmwIHj1cYFvKEiXVlXDJINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKGOjcHnscIFzgSC2dXLlJJNxem:3dHnu[{BifCBzMDDuUUBi\nSncjCxOEBpenN?	M{HXSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4NEe0N\|g4Lz5zNkS3OFM5PzxxYU6=
HUVEC	Mk\tSpVv[3Srb36gZZN{[Xl?	NH2wS\|IyODBibl2=	NUfpSJdzOTRiaILz	NH63eJRKdmirYnn0bY9vKG:oIF\HSnIudWWmaXH0[YQh[W6paX;n[Y5me2m\|IHnuJIh2dWGwIFjVWmVEKGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIHPhdIltdGG{eTD0eYJmKHOycn;1eIlv\yCjdDCxNFAhdk1iYX\0[ZIhOTRiaILz	MmjoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ2N{SzPFcoRjF4NEe0N\|g4RC:jPh?=
SJ-GBM2	M2\iO5FJXFNiYYPzZZk>			MnLXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	NFvEVZdyUFSVIHHzd4F6			NXPqe2hCeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	MUHxTHRUKGG\|c3H5			MoHkdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	NVjXT2txRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	M3yxd5FJXFNiYYPzZZk>			NX71fFN6eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz	NGKxT2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	M3zNSZFJXFNiYYPzZZk>			MX7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?=	NXXSdVRsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	M4XJXZFJXFNiYYPzZZk>			MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	NHTwc5k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	M2DzNpFJXFNiYYPzZZk>			MnuwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	NVrhbW9RRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	Mn;xdWhVWyCjc4PhfS=>			NXjqW5M2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	M{PZWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	MoXZdWhVWyCjc4PhfS=>			M1fiZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	M17PXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MV;xTHRUKGG\|c3H5			Ml:xdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
fibroblast cells	NEDqW25yUFSVIHHzd4F6			M2PueZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiClb370do9tKEiqIIfpcIQhfHmyZTDmbYJzd2KuYYP0JINmdGy\|	M3zKWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	MlLGdWhVWyCjc4PhfS=>			MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	NUTUdmJDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pFGFR2 / FGFR2 ; PubMed: 24968263 PLoS One PD173074 and MK2461 inhibit FGFR2 phosphorylation. Cells were treated for 1 hour with a titration of PD173074 as described in Materials and methods. Lysates were prepared and 50 ug protein was subjected to SDS-PAGE and western blotting with phospho Y653/654 FGFR and MAB6841 total FGFR2 antibody. p-S6RP / p-PRAS40 / p-p105 NFKB / P105 NFKB / P50 NFKB / p-AMPK / p-CRK II / p-PDK1; PubMed: 24968263 PLoS One Time course of inhibition for multiple signaling proteins. NCI-H716 cells were treated with 100 nM PD173074 for the indicated times and signaling pathways were analyzed by SDS PAGE and western blotting. 100 nM PD173074 was selected because this amount caused full inhibition of pERK at the 2 hour time point. “p” indicates phosphoprotein, and the phosphorylation sites are listed in Methods. Terminology on the right side of figure groups proteins according to the time at which inhibition or protein loss occurs.	24968263
Growth inhibition assay	Cell viability; PubMed: 24968263 PLoS One B. PD173074 and MK2461 inhibit NCI-H716 cell growth. Cell lines were plated at 4000 cells/well and incubated overnight. NCI-H716 cells were treated with a titration of PD173074 as described in Materials and Methods. Cell growth was measured with Vialight reagent, and growth was presented relative to untreated cells. C. PD173074 and MK2461 selectively inhibit growth of NCI-H716 cells. Colon cancer cell lines listed were plated at 4000 cells/well and 24 hours later were treated with a titration of compounds. 4 days later cell growth was measured with vialight and IC50s were calculated from graph pad prism.	24968263

In vivo

Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. ^[1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. ^[4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. ^[5]

Protocol

Kinase Assay:^[1]	- Collapse In vitro kinase inhibition assays: Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl₂, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-³²P]ATP (5 μM ATP containing 0.4 μCi of [γ-³²P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [³²P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:^[4]	- Collapse Cell lines: KMS11 and KMS18 Concentrations: Dissolved in DMSO, final concentrations ~100 nM Incubation Time: 48 hours Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Swiss Webster mice with induced corneal angiogenesis Dosages: ~2 mg/kg/day Administration: Administered intraperitoneally (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL (190.95 mM)
	Ethanol	100 mg/mL (190.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD173074 SDF

Molecular Weight	523.67
Formula	C₂₈H₄₁N₇O₃
CAS No.	219580-11-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCN(CC)CCCCNC1=NC2=NC(=C(C=C2C=N1)C3=CC(=CC(=C3)OC)OC)NC(=O)NC(C)(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the half-life of PD173074(S1264) in vivo?
Answer:
According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Pan FGFR Inhibitor

BGJ398 (NVP-BGJ398) : FGFR1/2/3-selective, IC50=0.9 nM/1.4 nM/1 nM.
Most Potent FGFR Inhibitor

AZD4547 : FGFR1, IC50=0.2 nM; FGFR2, IC50=2.5 nM; FGFR3, IC50=1.8 nM.
FDA-approved FGFR Inhibitor

Ponatinib (AP24534) : Approved by FDA for resistant or intolerant CML and Ph+ ALL.
Newest FGFR Inhibitor

SSR128129E ^New : Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

Related FGFR Products

Zoligratinib (Debio-1347) ^New

Zoligratinib (Debio-1347, CH5183284, FF284) is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.
BLU9931 ^New

BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. PX-478 2HCl induces apoptosis and has anti-tumor activity. Phase 1.
Infigratinib (BGJ398)

Infigratinib (BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.
AZD4547

AZD4547 (ABSK 091) is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.

Features:Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.
SSR128129E

SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.
LY2874455

LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
Dasatinib (BMS-354825)

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Choose Your Country or Region

By Signaling Pathways

By product type

PD173074